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Abstract Recommendations stated in the TASC II guidelines for the treatment of
peripheral arterial disease (PAD) regard a heterogeneous group of patients ranging from
claudicants to critical limb ischaemia (CLI) patients. However, speciﬁc considerations
apply to CLI patients. An important problem regarding the majority of currently available
literature that reports on revascularisation strategies for PAD is that it does not focus on
CLI patients speciﬁcally and studies them as a minor part of the complete cohort. Besides
the lack of data on CLI patients, studies use a variety of endpoints, and even similar
endpoints are often differentially deﬁned. These considerations result in the fact that
most recommendations in this guideline are not of the highest recommendation grade.
In the present chapter the treatment of CLI is not based on the TASC II classiﬁcation
of atherosclerotic lesions, since deﬁnitions of atherosclerotic lesions are changing along
the fast development of endovascular techniques, and inter-individual differences in
interpretation of the TASC classiﬁcation are problematic. Therefore we propose a
classiﬁcation merely based on vascular area of the atherosclerotic disease and the lesion
length, which is less complex and eases the interpretation.
Lesions and their treatment are discussed from the aorta downwards to the infrapopliteal
region. For a subset of lesions, surgical revascularisation is still the gold standard, such
as in extensive aorto-iliac lesions, lesions of the common femoral artery and long lesions
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of the superﬁcial femoral artery (>15 cm), especially when an applicable venous conduit
is present, because of higher patency and limb salvage rates, even though the risk of
complications is sometimes higher than for endovascular strategies.
It is however more and more accepted that an endovascular ﬁrst strategy is adapted in
most iliac, superﬁcial femoral, and in some infrapopliteal lesions. The newer endovascular
techniques, i.e. drug-eluting stents and balloons, show promising results especially in infra-
popliteal lesions. However, most of these results should still be conﬁrmed in large RCTs
focusing on CLI patients.
At some point when there is no possibility of an endovascular nor a surgical
procedure, some alternative non-reconstructive options have been proposed such as
lumbar sympathectomy and spinal cord stimulation. But their effectiveness is limited
especially when assessing the results on objective criteria. The additional value of cell-
based therapies has still to be proven from large RCTs and should therefore still be conﬁned
to a research setting.
Altogether this chapter summarises the best available evidence for the treatment of
CLI, which is, from multiple perspectives, completely different from claudication. The
latter also stresses the importance of well-designed RCTs focusing on CLI patients reporting
standardised endpoints, both clinical as well as procedural.
© 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Recommendations stated in the TASC II guidelines for the
treatment of peripheral arterial disease (PAD) regard a
heterogeneous group of patients ranging from claudicants
to critical limb ischaemia (CLI) patients. However, speciﬁc
considerations apply to CLI patients. CLI is characterised
by multi-level disease, high burden of comorbidity and
limited life span. Thus decision-making in revascularisation
strategies in CLI differs substantially from that in patients
with claudication as wound healing, limb salvage and
maintained ambulation are different treatment aims than
improved walking ability and there are often considerable
time constraints. Long-term patency as such is probably of
less importance. The choice of endovascular treatment may
be supported by presence of major comorbidities and hence
high risk for open interventions.
A minority of studies speciﬁcally addresses CLI, precluding
optimal decision for this speciﬁc group of patients. Moreover,
different outcome measures are reported in the scarce
studies that speciﬁcally focus on CLI patients. Some studies
address the success of the primary intervention, exempliﬁed
by primary patency rates, while others emphasise the
clinical results, such as limb salvage rates. The former
is of major importance to evaluate the success of the
intervention per se and the latter seems to be more
important from a patient’s perspective. So, in our opinion
both should be reported in clinical studies and in a more
standardised fashion as well.1 An important problem related
to the use of limb salvage as a measure of treatment success
is that it is a composite endpoint affected by a variety
of factors besides the revascularisation procedure per se.
Therefore it is a valid endpoint only in randomised controlled
trials. From a larger perspective, amputation-free survival
has been suggested to be the most important endpoint for
therapeutic studies on CLI.2
Most publications so far have been case series, cohort
studies or case––control studies. The availability of well-
conducted randomised controlled trials in this ﬁeld is limited
and therefore most recommendations in these guidelines
are based on a low level of evidence. This underlines the
need for future research that speciﬁcally addresses CLI
in a prospective randomised-controlled fashion with well-
circumscribed standardised reported outcomes.
2. Aorto-iliac revascularisation
Aorto-iliac arterial occlusive disease (AIOD) may lead to CLI,
especially if concomitant atherosclerotic disease of infra-
inguinal and/or below-the-knee (BTK) arteries is present.
Surgical repair with aorto(bi)femoral bypass grafting
or aorto-iliac endarterectomy has proven effective in
alleviating ischaemic pain and providing good long-term
patency. Aorto(bi)femoral bypass is the most efﬁcient
procedure in case of diffuse aorto-iliac disease but carries
substantial risk of peri-operative mortality, morbidity and
delay in return to normal activities.
An alternative approach is represented by endovascular
techniques that include angioplasty, stents, stent-grafts,
and plaque debulking, which offer both good clinical
and procedural results and have lower procedure-related
morbidity and mortality.
There are no RCTs directly comparing surgical vs.
endovascular treatment of AIOD. As a result, the selection of
the optimal approach for a patient with aorto-iliac occlusive
disease should be based on several variables, including an
assessment of the patient’s general condition and extension
of the disease.
2.1. Surgical treatment of AIOD
Anatomical open surgical arterial reconstructions for treat-
ment of AIOD are: aortofemoral bypass (AFB), iliofemoral
bypass (IFB), aorto-iliac endarterectomy (AIE). In rare cases
a further alternative is an extra-anatomic reconstruction by
descending thoracic aortofemoral bypass (DTAF).
Aorto(bi)femoral bypass is generally the preferred
treatment for diffuse aorto-iliac disease in patients who
are acceptable surgical candidates. Proximal anastomosis
is generally performed in an end-to-end or end-to-side
fashion at the level of the infrarenal aorta, without
important differences between the two techniques.3 The
simplest procedure that maintains adequate pelvic and
colonic blood supply, according to angiographic ﬁndings,
should be selected. The use of knitted gelatine-coated
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polyester, knitted collagen-coated polyester or stretch
polytetraﬂuoroethylene (PTFE) has been reported with
comparable results in terms of primary and secondary
patency and long-term complication rates.4––6 A MEDLINE
(1970––2007) and Cochrane Library search for articles that
report results of different open-surgical approaches for
arterial reconstruction for AIOD was recently published.
Studies reporting long-term primary patency data following
open anatomical repair of AIOD were included, for a total of
5738 patients treated by AFB, 778 by IFB and 1490 by AIE.7
The operative mortality rate for AFB, IFB and AIE was
4.1%, 2.7% and 2.7%, respectively (p < 0.0001), while the
systemic morbidity rate was 16% for AFB, 18.9% for IFB and
12.5% for AIE (p < 0.0001). In a sub-analysis according to
clinical presentation, the 5-year primary patency in case
of CLI was 79.8%, 74.1% and 81.7% for AFB, IFB and AIE,
respectively (p = 0.06), signiﬁcantly worse in comparison
to 5-year patency rates for patients with intermittent
claudication (p < 0.0001).
All three anatomical techniques for open-surgical aorto-
iliac reconstructions were equally effective in terms of
primary patency rates, but AIE appears to be associated
with signiﬁcantly lower operative mortality and systemic
and local complication rates compared to the two bypass
procedures. This can probably be explained by the fact that
AIE is utilised predominantly for localised aorto-iliac disease
and AFB and IFB may be used for more extensive disease.
DTAF is predominantly reserved for patients in whom
the aforementioned reconstructions are unsuitable and is
associated with higher operative mortality and graft-related
complication rates and lower 5-year patency rates than the
other three techniques.7––9
Recommendations
Aorto(bi)femoral bypass is generally the preferred treat-
ment for diffuse aorto-iliac disease in patients who are
suitable surgical candidates. (Level 2a; Grade B)
Aorto-iliac endarterectomy is to be recommended for
patients with suitable occlusive lesions as it appears to
be associated with signiﬁcantly lower operative mortality
and systemic and local complication rates compared with
bypass procedures. (Level 4; Grade C)
Descending thoracic aortofemoral bypass is to be reserved
for patients that cannot be otherwise revascularised
as it is associated with higher operative mortality and
graft-related complication rates and lower patency rates.
(Level 5; Grade D)
2.2. Laparoscopic repair
A variety of different techniques are encompassed in the
term laparoscopic AIOD repair, including totally-laparoscopic
repair, hand-assisted laparoscopic repair and robotic-
assisted laparoscopic repair. These are considered together
for the purposes of these guidelines. Laparoscopic repair
offers patients a third option for AIOD repair that provides
the durability of an “open” sutured graft with a rapid
recovery and reduced length of hospital stay.10,11
Currently, the role of laparoscopic repair remains limited
and should be conﬁned to centres with speciﬁc expertise
in laparoscopic aortic repair. This is in part due to the
requirements for advanced laparoscopic practice, and also
due to the steep learning curve for this procedure. It
should be noted that the cardiac risk of laparoscopic
procedures should be considered to be the same as for open
repair.12 Procedures should initially only be conducted under
supervision by someone experienced in laparoscopic aortic
repair. Facilities to deal with emergency surgical conversion
should be available at all times.
Recommendation
The role of laparoscopic repair of AIOD remains limited,
but in selected patients it might represent a third option
for aorto-iliac atherosclerotic disease repair. (Level 5;
Grade D)
2.3. Extra-anatomical bypass
Extra-anatomical arterial reconstructions such as axillo-
(bi)femoral bypass and crossover femoral bypass are
generally reserved for patients with increased comorbidities
or a hostile abdomen. For isolated unilateral iliac artery
occlusive disease, for which endovascular angioplasty failed
or does not seem feasible, a crossover femoro-femoral
bypass can be considered as effective as an aorto-femoral or
iliofemoral bypass, but with less operative morbidity. Extra-
anatomical repair also allows to preserve the autonomic
nerve ﬁbres at the aortic bifurcation and has less inﬂuence
on sexual function.
Recommendation
Because of the relatively low patency rates, extra-
anatomical bypass should be reserved for patients who
have no other alternatives for revascularisation. (Level 4;
Grade C)
2.4. Endovascular treatment of aorto-iliac occlusive
disease
There are no RCTs directly comparing surgical vs. endovas-
cular treatment of AIOD, and therefore there is a lack of
objective grounds on which the choice between the two
techniques can be made.
In clinical practice, because of its minimal invasiveness,
many clinicians consider endovascular therapy to be the ﬁrst-
line strategy, feasible and effective for the treatment of the
majority of aorto-iliac atherosclerotic lesions. The technical
success rate of angioplasty of iliac stenosis is nearly 100%,
and the technique is also used to treat long-segment iliac
occlusion. Unfortunately, CLI is seldom caused by limited
aorto-iliac lesions but rather occlusive disease affecting
multiple arterial segments. If focal lesions are identiﬁed,
they mostly cause an inﬂow problem above infrainguinal
occlusions in these patients.
2.4.1. Endovascular treatment of extensive aorto-iliac
occlusive disease
A recent systematic review performed by Jongkind et al.13
identiﬁed 19 non-randomised cohort studies reporting on
1711 patients with extensive AIOD. Although the lesions
treated were described adequately, unfortunately no data
on the indication were included. Technical success was
achieved in 86––100% of the patients with extensive AIOD,
deﬁned as less than 30% residual diameter stenosis and/or
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a residual trans-lesion pressure gradient of less than
10mmHg. Clinical symptom improvement was observed
in 83––100% of the patients, and mortality ranged from
1.2% to 6.7%. Although a number of procedural or peri-
operative complications were reported, including distal
embolisation, access-site haematomas, pseudoaneurysms,
arterial ruptures, and arterial dissections, the majority could
be treated using percutaneous or non-invasive techniques.
Four- and 5-year primary and secondary patency after
endovascular treatment of these extensive aorto-iliac lesions
ranged from 60% to 86% and 80% to 98%, respectively.
In two studies retrospectively comparing endovascular
therapy vs. open-surgical reconstruction for extensive AIOD,
a signiﬁcantly lower long-term primary patency was reported
for endovascular therapy (69% vs. 93%, p = 0.01314 and
74% vs. 93%, p = 0.00215), while secondary patency did not
differ signiﬁcantly (89% vs. 100% and 96% vs. 96%). The
applicability of these data on treatment decisions for CLI is
affected by the low proportion of patients with CLI in these
studies, 21%14 and 40%.15
Recommendations
Endovascular treatment can be considered a successful
primary strategy for patients with aorto-iliac lesions, most
often before or in conjunction with a distal revascu-
larisation. Its major advantage is its less invasiveness,
characterised by a lower operative morbidity-mortality.
(Level 3a; Grade C)
Even though primary patency rates after endovascular
therapy for extensive AIOD are inferior to those
reported after surgery, re-interventions may be performed
percutaneously. (Level 5; Grade D)
2.4.2. Plain balloon angioplasty vs. primary stenting
Although primary stenting has been proposed as more effec-
tive than plain balloon angioplasty for iliac atherosclerotic
lesions, the evidence described in the literature does not
allow clear conclusions.
The only RCT comparing the technical results and clinical
outcomes of two treatment strategies (primary stenting
or PTA followed by selective stenting when haemodynamic
results were inadequate) concluded that patients treated
with PTA and selective stent placement in the iliac artery had
a better outcome for symptomatic success compared with
patients treated with primary stent placement, whereas
data about iliac patency, ABI, and quality of life did not
support a difference between groups.16 Notably, the trial
was performed in a cohort of patients with lifestyle-limiting
intermittent claudication.
Nonetheless, primary stenting is now preferred in most
studies for extensive aorto-iliac lesions, considering the fact
that primary stenting without pre-dilatation is considered
to involve less risk of causing vessel rupture and/or distal
embolisation.
Recommendation
Angioplasty followed by selective stenting for PTA with
inadequate result should be preferred for iliac artery
occlusive disease. (Level 2; Grade B)
3. Infrainguinal disease
3.1. Common femoral artery (CFA)
Surgical endarterectomy of CFA lesions (CFE), isolated or
within a hybrid setting, provides excellent 1- and 5-year
patency rates of 93% and 91%, respectively, and secondary
patency rates reaching 100%.17,18 Ballotta et al. conﬁrmed
the excellent long-term patency of CFE with a patch in
a cohort of 117 patients (40% CLI) with 7-year primary
patency rates of 96%, assisted primary patency of 100%, and
100% limb salvage.19 An advantage of surgical treatment of
atherosclerotic disease of the CFA is that it provides the
potential to endarterectomise adjacent diseased segments
of the deep femoral artery (DFA) and the proximal superﬁcial
femoral artery (SFA) or the opportunity for hybrid iliac or SFA
recanalisation. It should be noted, however, that CFE per se
can also worsen pathology of the SFA.
There are reports on treating CFA lesions with endovascu-
lar techniques as well, although with variable results.20––24
In particular the early reports on angioplasty of the CFA
without stenting have been associated with relatively poor
results.25 However, technical success rates of 100% of CFA
angioplasty with primary stenting have been reported with
acceptable mid-term outcome.26 However, placing a stent
in the CFA may increase risk of potential future surgical
interventions and limit future access for endovascular
revascularisation in this location. CFA stenting is likely to
be an alternative for special indications and therefore RCTs
comparing it with endarterectomy are hardly possible. It
is further characterised by an increased risk of stent-strut
fracture in this mobile segment of the arterial tree, due
to repetitive hip ﬂexion––extension and compression by the
inguinal ligament.
Recommendation
Endarterectomy of atherosclerotic disease of the common
femoral artery provides excellent results with limited
morbidity and mortality and is the standard treatment in
this location. (Level 4; Grade C)
3.1.1. Hybrid procedures
Concomitant disease of the external iliac artery (EIA), DFA
or SFA is commonplace in CLI. In patients in whom CFE is
to be performed, the direct access via the CFA can offer
the opportunity to simultaneously perform endovascular
treatment of the adjacent diseased EIA or SFA. These hybrid
procedures have been performed with promising results and
acceptable patency rates.18 Hybrid procedures of the aorto-
iliac segment will be discussed here and the infrainguinal
hybrid procedures will be discussed in section 3.3 on
treatment of the SFA.
Aorto-iliac hybrid procedures often combine CFA surgery
or infrainguinal femoropopliteal bypass surgery with aorto-
iliac recanalisation, where the surgical part provides the
access for the endovascular reconstruction of the diseased
aorto-iliac segment. Initial technical success rates of
hybrid aorto-iliac intervention generally approach 100%
and peri-operative mortality rates are low.27––29 Reported
primary patency rates after hybrid procedures for aorto-iliac
occlusive disease are probably somewhat lower than for sole
endovascular interventions of the aorto-iliac segment,29,30
with 5-year primary patency rates of 60% for hybrid
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procedures29 and 4-year primary patency rates of 68%
(65––71%) and 77% (72––81%) for PTA and PTA with stenting,
respectively.31 Chang et al. showed improved patency rates
for stent grafts compared to bare-metal stents.29 A recent
report by Dosluoglu and co-workers32 reports similar results
of open, endovascular and hybrid techniques for patients
with similar disease complexity and even better limb salvage
rates in CLI patients with complex hybrid revascularisations
(TASC C or D).
Recommendations
Endovascular treatment of aorto-iliac occlusive disease
in a hybrid fashion offers an acceptable alternative
treatment in patients with aorto-iliac disease and
concomitant common femoral artery disease that requires
open surgery. (Level 3b; Grade C)
Stent grafts probably provide better results compared to
bare-metal stents in the hybrid treatment of aorto-iliac
occlusive disease. This should however be conﬁrmed by
future prospective studies. (Level 4; Grade C)
3.2. Deep femoral artery (DFA)
Profundoplasty is of limited value in the treatment of CLI,
but can be considered in patients with stenotic lesions of the
DFA and where restoration of continuous blood ﬂow from
the aorto-iliac tract to the SFA or popliteal artery is not
an option. Limb salvage rates of profundoplasty have been
reported to be 67% after 1 year33 and 49% and 36% after 3 and
5 years, respectively.34––37 Profundoplasty is rarely performed
as an isolated procedure and can be performed with or
without a patch based on the intra-operative judgment
by the surgeon. Besides its role for potential limb salvage
profundoplasty can be of value in preserving the knee joint
when amputation is deemed inevitable.34
Studies on endovascular treatment of DFA obstructive
disease have been mainly conﬁned to relatively small
case series, and long-term limb salvage rates are usually not
reported.38––43 Initial technical success rates of percutaneous
DFA recanalisation range from 77% to 100%,44 but long-term
results seem less favourable.24,43 However, more promising
results of endovascular treatment of the DFA were published
recently by Donas et al. in a selected group of patients
(n = 15) with CLI with sufﬁcient run-off vessels, in which
3-year primary and secondary patency rates were 80% and
86.7%, respectively, and limb salvage was 93%.45 Stenting of
the DFA has also been reported,26 but stenting the DFA likely
hampers potential future surgical interventions in this area.
Recommendations
Revascularisation of the deep femoral artery can be
considered in CLI patients without options for restoration
of continuous blood ﬂow from the aorto-iliac segment to
the popliteal artery in conjunction with haemodynamically
signiﬁcant stenosis of the DFA. Based on currently
available evidence, surgical profundoplasty is preferred
over endovascular recanalisation, due to a relatively high
rate of late failures of the latter. (Level 3b; Grade C)
Profundoplasty can be of additional value in preserving
the knee joint when amputation is inevitable. (Level 4;
Grade C)
3.3. Superﬁcial femoral artery (SFA)
In the present guideline, lesions of the SFA are not
classiﬁed according to the TASC II guidelines,46 though
these are generally regarded as the standard method of
classiﬁcation in treating peripheral arterial disease. The
deﬁnitions of atherosclerotic lesions are changing with the
rapid development of mainly endovascular techniques and
devices (TASC I vs. TASC II). Furthermore, the use of the
TASC classiﬁcation may be problematic due to considerable
inter-individual differences in interpretation.47––49 However,
since the widespread use of the TASC classiﬁcation system
in the past decades most studies used this method to
classify lesions under investigation. Therefore the TASC
classiﬁcation is still mentioned repeatedly in this guideline,
but is eliminated from the treatment recommendations. For
future use in research and for treatment recommendations
we propose a classiﬁcation system based on lesion length
instead of complex loco-anatomic descriptions of lesions as
provided by the TASC classiﬁcation.
3.3.1. Endovascular treatment
Endovascular treatment is increasingly considered as the
ﬁrst-line treatment for atherosclerotic lesions of the femoro-
popliteal segment. Yet, the success rate of endovascular
treatment of femoropopliteal lesions depends on variables
such as the presence of diabetes mellitus or chronic kidney
disease, stenosis vs. occlusion, lesion length and crural
run-off status,50 factors which are often unfavourable in
patients with CLI.51,52 Despite excellent initial technical
and clinical success rates of PTA of femoropopliteal artery
stenoses in series studying the full range of peripheral
arterial disease –– most including less than 15% CLI patients ––
the data for CLI are far worse. This was illustrated by a meta-
analysis of Muradin et al.,53 which showed clearly inferior
3-year primary patency rates after recanalisation of SFA
occlusions in CLI patients compared to claudicants.
Technical failure of angioplasty due to dissection or recoil
has been largely reduced with the introduction of the
bare metal stents,54 but restenosis has remained a major
problem precluding long-term beneﬁt of stenting. Yet, a
meta-analysis reported a 3-year patency rate of 58––68% in
CLI patients.53
The self-expanding nitinol stents have further improved
endovascular treatment of the SFA and provide more
durable results than stainless steel (balloon-expandable)
stents.55––60 Despite the fact that these studies mainly
included claudicants (proportion of CLI patients 14––89%),
results of self-expanding nitinol stenting seem beneﬁcial
in CLI patients as well. Primary nitinol stenting proved
beneﬁcial compared to PTA with provisional stenting
especially for longer SFA lesions (average lesion length
varying from 9.8±5.4 cm to 20.35±9.46 cm).61––65 Limb
salvage rates 36 months after stenting of the SFA in
CLI patients have been reported to be 67––75%.66,67
For lesions <5.0 cm in length the beneﬁt of pri-
mary stenting is clearly more debatable as has been
shown in a meta-analysis by Kasapis and colleagues,68
who showed no differences in restenosis rate and
target vessel recanalisation, despite a higher imme-
diate success rate for stenting compared to angio-
plasty alone.
Different studies have been published supporting endovas-
cular treatment of long femoropopliteal (TASC C and D)
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lesions with or without stenting. Han and co-workers
published their results of endovascular treatment stratiﬁed
by TASC lesion type and showed that in 243 CLI patients
limb salvage rates 24 months after endovascular treatment
were 81.0±12.9%, 81.1±6.8%, and 71.9±8.0% for TASC A+B,
TASC C and TASC D lesions of the SFA, respectively.69
Similar limb salvage rates were obtained by Taneja and
co-workers in CLI patients with long-segment occlusions
(average 23.8 cm, range 10––39 cm) treated with bare nitinol
stents, however primary patency rates were rather low
with 61.5% and 27% after 6 and 12 months, respectively.70
These studies suggest that endovascular treatment of long
femoropopliteal lesions can be –– at least clinically ––
successful.
The high restenosis rates of bare nitinol stents observed
mainly in long atherosclerotic lesions of the SFA and
the popliteal region provide the fertile soil for further
technical innovations aiming at increasing patency rates. An
important and promising innovation has been the stent graft
(also referred to as covered stent, endograft, endoluminal
bypass or thrupass). Most stent grafts are composed of
nitinol stents covered with polytetraﬂuoroethylene (PTFE)
and were developed to prevent restenosis due to intimal
hyperplasia. Primary patency rates after 1 year for
lesions <10 cm treated with PTFE stent grafts have been
reported to be approximately 90% in CLI.71,72 However,
lower and considerably varying 1-year patency rates have
been recorded for longer lesions of the SFA treated
with PTFE stent grafts, ranging from approximately 48%
to 81%,73––78 and generally lower patency rates are observed
in CLI patients and occlusive lesions. Despite a 69% primary
patency rate at 3 years, Alimi et al. reported a 86%
limb salvage rate in CLI patients treated with the PTFE
stent graft for lesions with a mean length of 12.4 cm (range
2.6––30.2 cm).76
Studies directly comparing stent grafts with plain PTA or
PTA with bare stents are very limited. Saxon et al. compared
stent grafts (n = 97, 9% CLI) with PTA alone (n = 100, 12% CLI)
in a randomised fashion for treatment of SFA lesions (stenosis
or occlusions) up to 13 cm. In the stent graft group a higher
technical success rate and 1-year primary patency rate of
65% vs. 40% (p = 0.0003) was observed.79 The preliminary
results of the VIBRANT trial that compares angioplasty
of long SFA lesions with either the PTFE stent graft or
bare nitinol stenting do not show any differences regarding
primary patency at 1-year follow-up; however, secondary
patency at 1 year was somewhat higher in the stent graft
group. The ofﬁcial mid-term (3 years) follow-up results
are not yet available but could prove superiority of one
of both treatment modalities. An FDA-approved heparin-
bonded version of the stent graft has been developed to
improve patency rates. Future randomised trials still have
to prove the efﬁcacy and superiority of (heparin-bonded)
stent grafts over bare nitinol stents.
There is one major concern of using covered stents,
namely the potential loss of pre-existent collateral vessels
with acute deterioration in case the stent graft occludes;
however, this hypothesis is not yet conﬁrmed by evidence.80
Another proposed strategy to prevent intimal hyperplasia
is represented by drug-eluting stents (DES). The ﬁrst piloting
trials (SIROCCO I& II) comparing sirolimus-coated stents with
bare nitinol stents in the SFA failed to show important
and signiﬁcant differences between the two treatment
groups.81,82 Currently there are two trials, which have not
yet published their results, that study the paclitaxel-coated
Zilver pTX stent (Cook Medical, Bloomington, Indiana, USA)
and the everolimus-eluting Dynalink-E (Abbott Vascular,
Abbott Park, Illinois, USA), the Zilver pTX trial and the
Strides study, respectively. In the Zilver pTX trial patients
with moderate to severe symptomatic femoropopliteal
artery disease (lesions up to 14 cm; average lesion length
6.6 cm) were randomised to undergo either traditional PTA
or PTA plus Zilver pTX stent deployment (n = 479). In the
PTA group non-optimal (>30% residual stenosis or >5mmHg
pressure gradient) PTAs were again randomised to either
subsequent deployment of a bare Zilver stent or the
pTX version of the stent. The preliminary short-term results
of the Zilver pTX trial are promising, with 12-month patency
rates in the provisional stent group (after suboptimal PTA)
of 89.9% and 73% for the Zilver pTX and bare Zilver stent,
respectively (p = 0.01). These results seem to be consistent
and are conﬁrmed by the 2-year follow-up data, where
primary patency rates in the provisional stent group are
81.2% (n = 56) and 62.7% (n = 56) for the Zilver pTX and the
bare-metal Zilver stent, respectively. On the other hand the
Strides study (n = 106; mean lesion length 9.0±4.3 cm; 17%
CLI patients) did not show any beneﬁt of the everolimus-
eluting Dynalink-E stent compared to historical controls
treated with a similar non-everolimus-eluting stent, both
showing a primary patency of between 60% and 70% at
12 months, despite a promising 94±2.3% primary patency
rate of the former.83
Since long complex lesions are usually present in
CLI patients, successful endovascular recanalisation of the
SFA can sometimes only be performed with subintimal
angioplasty (SIA). SIA has been associated with high limb
salvage rates between 85% and 90% at 1 year, even despite
a low 50% 1-year primary patency rate.84 These results were
recently conﬁrmed by Bolia et al. and Setacci et al. with
primary success rates of 80% and 83.5% and limb salvage
rates of 85% and 88% at 1 year, respectively.85,86
A major concern of the popularity of endovascular
interventions, especially in complex lesions, is the potential
alteration of the level for subsequent open procedures after
failed endovascular intervention. Joels et al. have reported
that the problem of alteration of the level of a subsequent
open procedure after failed endovascular intervention is
acceptable and even when the level alters it does not
necessarily change clinical outcome.87 They showed that
only 23 out of the 276 patients subjected to endovascular
recanalisation of the SFA presented with early failure of the
procedure and that this altered the level of the subsequent
open intervention in one third of the patients. Amputation
due to early failure was necessary in only one patient (0.4%).
However, they did not include TASC D lesions. In another
study, by Gur et al.,88 of the 192 patients who underwent
PTA with primary stenting of the SFA, 69 stented arteries
lost primary patency (over a 5-year period). In 10 patients
open bypass was eventually required and the bypass level
was changed in two of them. The risk of stent failure,
loss of run-off vessels and necessity for open procedures
was higher in the TASC C and D lesions. The fact that
CLI patients are amenable to subsequent intervention (both
open and endovascular) for limb salvage even after failed
endovascular intervention is further supported by Ryer and
colleagues.89
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3.3.2. Surgery
Bypass surgery has long been and still is the gold standard
therapy in the treatment of long SFA lesions. The great
saphenous vein is the best performing conduit for infra-
inguinal bypass surgery. Above-the-knee femoropopliteal
bypass has a patency rate of 77.2% at 5 years in claudicants
and 69.4% in CLI patients, when saphenous vein is used as a
conduit. Autologous great saphenous vein bypass below the
knee has similar long-term patency rates compared to above
the knee bypass.90 Limb salvage rates of 86.9% (±7.6%)
2 years after non-reversed vein grafts in above-the-knee
femoropopliteal bypasses have been reported for CLI.91
Venous conduits outperform prosthetic conduits irrespective
of the material used (Dacron or PTFE). This also applies for
arm vein conduits compared to prosthetic bypasses in CLI
patients.92
The BASIL trial is the only randomised trial comparing
a PTA-ﬁrst vs. a bypass surgery-ﬁrst strategy in patients
with severe limb ischaemia; it showed no differences
in amputation-free survival between bypass surgery and
PTA. However, for patients with a more than 2-year
survival after the initial intervention, patients randomised
to bypass surgery showed higher overall and amputation-
free survival.93––95 The superiority of femoropopliteal bypass
procedures compared to femoropopliteal PTA in CLI patients,
especially in the long-term, is supported by a retrospective
study by Korhonen et al. which used a propensity score
analysis to minimise bias.96 They showed considerable
differences in favour of the bypass group (80.5% vein and
19.5% prosthetic graft) with 5-year limb salvage rates of
78.2% vs. 91.8% and survival rates of 49.2% vs. 57.1%
for the PTA and bypass group, respectively. These results
were still signiﬁcant in the propensity score-matched
pairs, with 5-year limb salvage rates of 74.3% vs. 88.2%
(p = 0.031) for the PTA vs. the bypass group, respec-
tively.
Bypass surgery has also been randomly compared with
stent graft procedures. Kedora et al.75 reported on 100
patients with SFA occlusive disease and symptoms ranging
from claudication to rest pain, with or without tissue
loss, who were randomised to PTA with one or more
self-expandable stent grafts (n = 50) or prosthetic femoral-
popliteal above-the-knee bypass (n = 50). The mean total
length of artery stented was 25.6±15 cm. Both 1-year
primary and 1-year secondary patency rates –– based on life-
table analysis –– were not signiﬁcantly different between the
two groups, with primary patency rates of 73.5% vs. 74.2%
and secondary patency rates of 83.9% vs. 83.7% for the
stent graft and bypass group, respectively. Neither did
limb salvage between the two groups differ signiﬁcantly.
Severity of limb ischaemia (Rutherford classiﬁcation) did
not differ between the two groups; however, ischaemia
showed a non-signiﬁcant tendency to be more severe
in the bypass group.75 Later results from the same
patient group showed a trend to lower patency rates
for the stent graft group in the higher TASC II lesions
(TASC C and D).78 Less favourable results for stent graft
procedures were reported by Lepa¨ntalo and co-workers in
a prematurely terminated (due to disadvantageous outcome
in the stent graft group) randomised multicentre trial
comparing stent graft procedures and prosthetic bypass
surgery for occlusions (TASC II B and C occlusions) of
the SFA.73 In contrast to the two other studies, which
mainly included patients with intermittent claudication and
did not clearly reveal data on concealment of treatment
allocation, Lepa¨ntalo et al. only included CLI patients
based on rigorous inclusion criteria and properly reported
concealment. They reported substantial lower primary and
secondary 1-year patency rates for the stent graft group vs.
the bypass group, 46% vs. 84% and 63% vs. 100%, respectively.
Overall the results of these studies still favour the use
of femoropopliteal bypass vs. stent graft procedures in
CLI patients with long SFA lesions, especially long occlusions.
Future RCTs comparing these treatment modalities (and
the heparin-bonded endograft) in speciﬁc subgroups of
CLI patients are necessary to allow deﬁnitive conclusions on
these therapies.
3.3.3. Hybrid procedures
Hybrid procedures combining CFA surgery or distal origin
bypass surgery with angioplasty of the SFA is another
possibility to treat lesions of the SFA. Hybrid procedures
studied are highly heterogeneous, therefore no exact
numbers can be provided on patency rates and limb
salvage rates. Patency rates after hybrid procedures
vary considerably, with 3-year primary patency rates
as high as 84% and primary patency rates as low as
58% after 41 months follow-up.32,97,98 However, reported
limb salvage rates 3 years after the intervention are
over 80%.32,97,99
In a hybrid procedure it is also possible to perform remote
superﬁcial femoral artery endarterectomy (RSFAE). Patency
rates of retrospective studies are promising so far, with
patency rates of 61––69% at 18––33 months.100 In the REVAS
trial, RSFAE compared with above-knee bypass surgery has
been studied for the treatment of TASC C and D lesions of the
SFA. Primary patency rates after 1 year were 61% for RSFAE
and 73% for bypass surgery, with similar secondary patency
rates of 79%.101
3.3.4. Drug-eluting balloon, cryoplasty, cutting balloon,
excimer laser
Drug-eluting balloons, successfully applied for angioplasty
of coronary arteries, have not been widely studied in
the femoropopliteal arteries. The available short-term
data on the use of drug-eluting balloons for PTA of the
femoropopliteal region are encouraging, however these
studies have mainly focused on relatively short lesions
and almost invariably address claudicants.102,103 Longer-
term follow-up and larger randomised trials are needed
to clarify whether drug-eluting balloons can be beneﬁcial
in the long term and should include sufﬁcient numbers of
CLI patients to draw reasonable conclusions in this subset of
patients.
No data exist on the direct comparison of cryoplasty,
cutting balloons and excimer laser with conventional
endovascular treatment in patients with CLI. Cryoplasty
seems not beneﬁcial in the femoropopliteal area.104,105
Cutting balloons have a short design thereby limiting their
use in long lesions of the SFA. Use of the excimer laser
has been shown to be effective in CLI,106,107 however there
is no evidence of superiority compared to conventional
angioplasty or subintimal angioplasty in CLI.
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Recommendations
A new and simpliﬁed classiﬁcation system for peripheral
arterial disease lesions is needed to improve inter-
individual interpretation as this is problematic for the
TASC classiﬁcation. Therefore we would recommend a
system based on lesion length to classify lesions for
research applications and clinical management (EUSC
classiﬁcation; Fig. 1). Future research should prove the
applicability and reproducibility of the classiﬁcation and
the additional value of a potential subdivision of stenotic
vs. occlusive lesions. (Level 5; Grade D)
Short SFA lesions (<5 cm) are preferably treated with
angioplasty. Stenting of short lesions should only be
performed when suboptimal results are obtained with
PTA alone. (Level 1a; Grade B)
The preferred treatment of intermediate SFA lesions
(5––15 cm) is PTA with primary bare nitinol stenting.
(Level 1b; Grade B)
The additional value of drug-eluting and PTFE stent grafts
still has to be conﬁrmed in CLI patients.
When autologous vein is available as a conduit, bypass
surgery is the preferred treatment for long SFA lesions
(>15 cm), especially in younger patients. Although the
outcome after an endovascular ﬁrst approach is equal
in the short term to prosthetic bypass surgery for long
SFA lesions in CLI patients, bypass gives better results in
more ﬁt patients and should be preferred in patients with
estimated longevity >2 years. (Level 1b; Grade B)
In long SFA lesions (>15 cm) endovascular treatment
(intraluminal or subintimal) with a stent graft seems
acceptable when the patient’s condition precludes an
open procedure. The value of the heparin-bonded stent-
graft has still to be conﬁrmed. (Level 3b; Grade C)
Hybrid procedures are the preferred treatment modality
irrespective of lesion length in high-risk patients not
suitable for open bypass surgery or when no suitable vein is
available if minimally open revascularisation is mandated,
such as CFE. (Level 2b; Grade B)
4. Infrapopliteal disease
Despite the magnitude of the problem –– currently greater
than ever due to the increasing diabetic and ageing
population –– unexpectedly little high-quality evidence exists
in the literature to support a strategy paradigm in patients
with CLI and infrapopliteal disease.
Several studies have demonstrated that surgical revas-
cularisation is the standard treatment for limb salvage
in patients with CLI due to atherosclerotic disease of
infrapopliteal arteries, but endovascular interventions of
infrapopliteal lesions represent a far less invasive option and
are now considered a valid alternative to surgical bypass in
many cases.
4.1. Surgical revascularisation for infrapopliteal lesions
Unfortunately, a detailed anatomical description of the
disease and relative localisation of the treatment is rarely
reported in RCTs and observational studies comparing
different treatments for CLI, and no speciﬁc conclusion can
be drawn for patients with isolated infrapopliteal disease.
The PREVENT III study108 was a prospective, randomised,
double-blinded, multi-centre phase III trial of a novel molec-
ular therapy (edifoligide; E2F decoy) to prevent vein graft
failure in patients undergoing infrainguinal revascularisation
for CLI, reporting a peri-operative mortality rate of 2.7%,
primary and secondary graft patency rates of 61% and 80%,
and 1-year limb salvage and survival rates of 88% and 84%,
respectively. In the majority of the 1404 patients who
underwent surgical bypass procedures (n = 914, 65%) the
bypass was anastomosed at the tibial or pedal/plantar
vessels distally, but no separate analysis of this subgroup
was provided.
In the BASIL trial,93––95 only 10% of distal bypass
anastomoses were located distally to the popliteal artery.
Moreover, the design of the trial included only patients
considered suitable for both surgical and endovascular
treatment, which means that very complex cases have been
treated outside the scope of the trial (probably by surgical
approach).
A set of suggested objective performance goals (OPG)
for evaluating the results of new catheter-based treat-
ments in CLI has recently been elaborated, based on
evidence from RCTs of patients treated by surgical
vein bypass. The patient-level data from three RCTs
identiﬁed 838 patients with autogenous vein bypass. The
primary efﬁcacy endpoint, deﬁned as freedom from peri-
operative (30-day) death or any major adverse limb event
(amputation or major re-intervention) occurring within
1 year was 76.9%, and the primary amputation-free survival
at 1 year was 76.5%. The authors suggest that these
data should be considered the most suitable current
framework for non-randomised comparisons, especially
for evaluating outcomes after endovascular treatments
for CLI. They also stress that risk stratiﬁcation should be
incorporated in design and reporting of studies since the
CLI population is heterogeneous and the OPG thresholds
differ substantially between the lower- and higher-risk
procedures (based on clinical, anatomical and conduit
characteristics).109
Although no RCTs have selectively studied the outcomes
of different graft materials for the construction of bypasses
to the infrapopliteal arteries, there is a large body of
evidence that vein offers better results in comparison
to other graft material. Both immediate and long-term
patency beneﬁt from the use of autologous great saphenous
vein, whether in situ or reversed. Proximal (CFA, SFA or
popliteal artery) and distal anastomoses (tibial and pedal
arteries) of infrainguinal bypasses may vary, depending
on the extent of the atherosclerotic disease. Since the
proposal of the “short bypass principle” by Veith110 in 1981,
the use of more distal sites for the origin of the bypass
have been recommended (popliteal-to-distal bypasses). The
advantages include the reduction of groin dissection, the
use of shorter graft material, and the decrease in operative
time.
A meta-analysis111 of popliteal-to-distal vein bypass grafts
reported a 5-year primary graft patency rate of 63±4%, a
secondary patency rate of 70±5%, and a foot salvage rate
of 78±4%.
When the great saphenous vein is unavailable or
unsuitable, alternative graft materials include autologous
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Fig. 1. EUSC classiﬁcation for SFA lesions and treatment advice. In view of problems with the use of TASC guideline classiﬁcation for
atherosclerotic lesions –– mainly poor inter-individual interpretation and hence problematic interpretation of treatment results published
in the literature –– we propose a simpliﬁed classiﬁcation based on lesion length rather than based on complex loco-anatomic descriptions.
Future research using this method has to prove its applicability and need for subclassiﬁcations, e.g., occlusive vs. stenotic lesions.
vein, allograft material (cryopreserved vein and arterial
allograft) and synthetic material such as PTFE. A meta-
analysis of allograft bypass grafting to infrapopliteal
arteries112 revealed a poor patency rate at 5 years
(ranging from 19% to 30% for different grafts: cold-storage
vein, cryopreserved arteries, umbilical-cord veins, and
cryopreserved veins) and reduced rate of foot preservation
(ranging from 55% to 60%).
Better results in cases of great saphenous vein absence
come from the use of alternative autologous vein. Although
this approach carries disadvantages such as the need to
harvest vein from distal sites and construction of composite
grafts, the meta-analysis of alternative autologous vein
bypass grafts to infrapopliteal arteries113 reported results
far superior to those reported for non-autologous grafts.
The 5-year pooled estimates were 46.9% for primary
patency, 66.5% for secondary patency, and 76.4% for foot
preservation. The radial artery (or arteries) can be used
for limb-salvage revascularisation when no other valuable
autologous veins are available. Only short case series have
been reported in the literature, almost all in diabetic
patients.114,115
The use of PTFE bypass to infrapopliteal arteries is
associated with poor long-term outcomes. Random-effects
meta-analysis116 yielded 5-year pooled estimates of 31% for
primary graft patency, 40% for secondary graft patency, and
56% for foot preservation. Outcomes were slightly higher for
a series of PTFE grafts with adjunctive procedures at distal
anastomoses (composite PTFE-vein grafts, patches, cuffs and
arteriovenous ﬁstulas), compared with a series of PTFE grafts
only.
Combinations of popliteal-to-distal bypass and endovascu-
lar treatment of SFA lesions have also been reported99,117 to
improve technical success and patency rate.
Recommendations
The great saphenous vein is superior to other materials
and should be preferred in bypass grafting to infrapopliteal
arteries. (Level 3b; Grade B)
When the great saphenous vein is unavailable or
unsuitable, the use of alternative autologous vein grafts
(single-segment or composite) is preferable to that




The primary aims of infrapopliteal angioplasty in CLI are
to restore at least one straight line of blood ﬂow to the
ischaemic foot and to maintain the patency of the treated
artery for as long as possible or at least as long as necessary
to allow ulcer healing, pain relief and to avoid recurrence
of CLI.
In the past, infrapopliteal angioplasty has been reserved
for patients with short stenotic lesions or for patients who
are poor candidates for bypass surgery, but in the last
5––10 years this technique has been used with increasing
frequency, also for more complex lesions. Due to the
evolution of techniques and the availability of dedicated
materials, the endovascular ﬁrst-line approach to below-the-
knee (BTK) vessels should be preferred over bypass according
to some authors.118––120
Different endovascular approaches have been proposed,
including ipsilateral, antegrade or contralateral retrograde
femoral puncture, or more recently, retrograde anterior or
posterior tibial puncture121,122 or retrograde crossing through
the pedal arch (pedal-plantar loop technique).123,124
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Unfortunately, the level of evidence for endovascular
treatment of BTK vessels is still low. Considering the absence
of RCTs comparing surgical vs. endovascular techniques
in patients with infrapopliteal disease, the most relevant
data in the literature come from extrapolations of RCTs
comparing the outcome of bypass and balloon angioplasty
at different levels in patients with CLI and from the meta-
analysis of retrospective case series where no biases were
detected.
Another way to try to decrease bias in comparisons is to
adjust differences by using propensity score analysis in large
patient cohorts.125,126 Recently, in a study cohort comprising
1023 patients treated for CLI with 262 endovascular and
761 surgical revascularisation procedures to their crural
or pedal arteries were compared. In the overall series,
PTA and bypass surgery achieved similar 5-year limb
salvage (75.3% vs. 76.0%), survival (47.5% vs. 43.3%), and
amputation-free survival (37.7% vs. 37.3%), indicating that
when feasible, infrapopliteal PTA as a ﬁrst-line strategy
is expected to achieve similar long-term results to by-
pass surgery in CLI when redo surgery is actively utilised. In a
subgroup of patients who underwent isolated infrapopliteal
revascularisation, PTA was associated with better limb
salvage (75.5% vs. 68.0%, p = 0.042).127 Additionally, in
584 consecutive patients aged at least 80 years treated
with either PTA (n = 277) or bypass surgery (n = 307) for CLI
irrespective of the level of infrainguinal revascularisation,
PTA achieved better results than bypass surgery after
2 years (leg salvage: 85.4% vs. 78.7%, p = 0.039; survival:
57.7% vs. 52.3%, p = 0.014; amputation-free survival (AFS):
53.0% vs. 44.9%, p = 0.005). Cox regression analysis showed
that increased age [relative risk (RR) 1.05, 95% conﬁdence
interval [CI] 1.02––1.08], decreased estimated glomerular
ﬁltration rate (RR 0.99, 0.99––1.00), diabetes (RR 1.30,
1.04––1.62), coronary artery disease (RR 1.36, 1.05––1.75)
and bypass surgery (RR 1.55, 1.24––1.93) were associated
with decreased AFS. In 95 propensity score-matched pairs,
limb salvage at 2 years (88% vs. 75%; p = 0.01) and AFS
(53% vs. 45%; p = 0.033) were signiﬁcantly better after PTA.
Classiﬁcation and regression tree analysis suggested that PTA
was associated with better 1-year AFS, especially in patients
with coronary artery disease (63.8% vs. 48.9%; p = 0.008).
When feasible, a strategy of PTA ﬁrst appears to achieve
better results than infrainguinal bypass surgery in patients
aged 80 years and older.128
Regrettably, the only major randomised trial comparing
PTA vs. surgery for peripheral arterial occlusive disease
(BASIL) included patients with infrainguinal rather than
isolated infrapopliteal lesions and did not report details
of the anatomic segments treated and relative outcomes.
Consequently, no extrapolation of data is possible, which
limits analysis of the results of angioplasty vs. surgery for
patients with isolated crural disease.
In a recent meta-analysis of infrapopliteal angioplasty
for CLI including a large number of case series, the
pooled estimate of success was 89.0±2.2% for immediate
technical results, and the early mortality rate was 1.8%.
The mid-term estimates of primary patency, secondary
patency and limb salvage were assessed reliably until
36 months.129 When compared to the results of the meta-
analysis of popliteal-to-distal bypass graft, the durability of
infrapopliteal angioplasty is limited, but the clinical beneﬁt
is acceptable because the limb salvage rate of 82% at
3 years is not inferior to that of surgical revascularisation,
which underlines that limb salvage does not only depend
on patency rates. Hence both patency rates and clinical
success should be assessed when evaluating a treatment
in CLI patients. Secondary interventions are much more
frequent after endovascular treatment of infrapopliteal
arteries. Repeated angioplasty attempts, which are not
always innocuous, have some advantages over repeat
bypass grafting, which is troublesome and not always
feasible.
Recommendations
Endovascular treatment of infrapopliteal arteries has
the potential to achieve similar limb salvage rates
with less procedural morbidity and mortality than
surgical bypass. Angioplasty as the ﬁrst-line therapeutic
modality for patients with CLI and infrapopliteal lesion
is reasonable in the majority of cases, considering that
the interventional procedure should not preclude future
surgical intervention. (Level 4; Grade C)
Surgical treatment should be considered for more
complex anatomical lesions of BTK vessels or in case
of endovascular failure and persisting clinical symptoms
of CLI. (Level 4; Grade C)
4.2.2. Stenting
New endovascular techniques have been proposed to
improve the results of plain angioplasty, including the use
of bare metal stent (balloon-expandable and self-expanding
stents), drug-eluting balloon and stent, cryoplasty, laser
and atherectomy. The data for these new technologies
still derive predominantly from a few small RCTs and from
retrospective case series, with a limited number of patients
and a relatively short clinical and instrumental follow-up.
Although the ﬁrst use of stents for infrapopliteal lesions
was reported more than 15 years ago,130 several concerns
have been raised regarding their utilisation with respect to
the risks of stent fracture, restenosis, thrombosis, and the
possibly limited role of a focally acting endoprothesis in a
diffusely diseased vessel.
4.2.2.1. Balloon-expandable stent: Fering et al.131 were
the ﬁrst to demonstrate the safety and utility of primary
stenting of infrapopliteal lesions using coronary stents, in a
large retrospective series.
The ﬁrst RCT on the topic was the InPeria trial published
by Rand et al.132 The trial was a European multi-centre
randomised study that investigated carbon-coated stents
(a 0.014-inch coronary balloon-expandable stent with a
thin coating of 0.5 nm of polycrystalline carbon ﬁlm to
prevent thrombus formation) vs. balloon angioplasty in
the infrapopliteal arteries. A total of 51 patients, with
95 lesions, were enrolled (PTA: 53 lesions in 27 patients;
stent: 42 lesions in 24 patients). Inclusion criteria were
isolated stenosis greater than 70% or occlusion of the
tibial arteries, up to three lesions; and lesions up to
3 cm with a cumulative lesion length of 9 cm. Follow-up
evaluation was performed with intra-arterial and/or CT
angiography at 6 months by two double-blind observers.
For the stent group, the cumulative primary patency at
6 months was 83.7% (70% restenosis threshold) and 79.7%
(50% restenosis threshold). For PTA, the primary patency at
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6 months was 61.1% (70% restenosis threshold) and 45.6%
(50% restenosis threshold) (p < 0.05). Although the results
at 6 months were superior in the stent group, 9-month
clinical follow-up of an extended 88-patient group (InPeria II;
45 limbs with 69 lesions treated with PTA vs. 44 limbs
with 62 lesions treated with Carbostents) showed similar
levels of clinical improvement and limb salvage (96% vs.
91%, respectively) and similar 1-year patency rates of
about 60%.133 Until now, longer follow-up data have not been
available.
Other authors reported positive results of primary stenting
using coronary balloon-expandable drug-eluting stents for
infrapopliteal disease in small, non-randomised, single-
centre studies.134––138 These studies show favourable clinical
results for drug-eluting stents in the early follow-up
period, with signiﬁcantly higher angiographic patency and
less clinically driven re-interventions compared to simple
angioplasty or bare-metal stent. However, these results have
to be interpreted with caution because these studies were
small in size and had limited follow-up. Notably most of
these studies were industry-sponsored.
More recently, data from three RCTs comparing new
solutions for infrapopliteal atherosclerotic disease have
been presented at international meetings139 (although
manuscript publications are still awaited). These trials have
found that drug-eluting stents are superior to angioplasty,
or bare metal stents, in below-the-knee revascularisation.
In particular, the ACHILLES trial has shown better primary
patency for sirolimus-eluting balloon-expandable stents in
the infrapopliteal region compared to balloon angioplasty,
and the YUKON and DESTINY trials have shown a similar
beneﬁt for drug-eluting stents below the knee (respectively,
a sirolimus-eluting stent and an everolimus-eluting stent)
as compared to a bare metal stent. However, no signiﬁcant
difference in limb salvage rate was observed.
Despite the encouraging results from these RCTs for
drug-eluting devices in infrapopliteal vessels, it should
be noted that several inclusion criteria present in the
protocols restricted study enrolment to patients with limited
manifestations of tibial atherosclerotic disease, including
patients with claudication (Rutherford 3) and excluding
patients with severe tissue loss (Rutherford 6).
Complete longer follow-up data including clinical end-
points and wound healing assessments are expected to be
published in the near future.
4.2.3. Self-expanding nitinol stents
The main restrictions of currently available bare or drug-
eluting balloon-expandable stent platforms for BTK vessels
are the small lengths available and the vulnerability to
external compression (especially in the distal third of the
anterior and posterior tibial artery). This is the reason
why the majority of available studies are limited to short
focal infrapopliteal lesions up to 3 cm, which are not
representative of typical long BTK lesions.
Long, thin-strut, low-proﬁle, self-expanding nitinol stents
designed and engineered speciﬁcally for the infrapopliteal
arteries are now commercially available, but clinical data
are still limited to small non-randomised studies.140––142
One RCT designed to compare PTA vs. self-expanding
stent (The XXS –– Balloon Angioplasty Versus Xpert Stent
in CLI Patients) in patients with infrapopliteal lesions has
recently completed the recruitment (180 CLI patients and
a maximum of 2 arteries with a maximum lesion length
of 150mm). Interesting data about subjects with very long
BTK lesions (which might better reﬂect real-world cases) are
expected shortly.
A collaborative systematic review and meta-analysis143
of clinical studies focusing on BTK stenting in patients
with CLI identiﬁed 18 non-randomised studies including
more than 600 patients. Data showed that bailout stenting
of BTK vessels, performed with either balloon-expandable
or self-expanding stents for suboptimal balloon dilation,
was associated with satisfactory results up to a median
of 12 months after treatment: binary in-stent restenosis
occurred in 25.7% (95%CI 11.6––40.0%), primary patency in
78.9% (95%CI 71.8––86.0%), improvement in Rutherford class
in 91.3% (95%CI 85.5––97.1%), target vessel revascularisation
in 10.1% (95%CI 6.2––13.9%), and limb salvage in 96.4%
(95%CI 94.7––98.1%). Subanalyses focusing on device type
showed that balloon-expandable and self-expanding stents
avoiding joint segments or pedal vessels perform similarly at
early and midterm follow-up. In addition, the available data
suggest superiority of sirolimus-eluting stents in comparison
to bare metal stents in terms of primary patency and need
for re-revascularisations.
Recommendation
Short, focal infrapopliteal lesions can be treated by drug-
coated or drug-eluting stents, with improved patency
rate. (Level 2b; Grade B)
4.2.3.1. Bioabsorbable stent: The possibility of not having
a permanent metallic implant (bioabsorbable stent scaffold
technology) has emerged as an exciting technology to
combine mechanical prevention of vessel recoil with the
advantages of long-term perspective. The bioabsorbable
stent could permit the occurrence of positive remodelling
with lumen enlargement to compensate for the development
of intimal hyperplasia or new lesions.
The ﬁrst published data with coronary application of an
absorbable polymeric everolimus-eluting stent were very
promising,144 revealing a nearly complete elimination of
both intimal hyperplasia and the need for re-interventions
at 1 year.
Unfortunately, the same promising results have not been
validated for BTK vessels. The prospective multi-centre
randomised trial investigating infrapopliteal absorbable
magnesium stents (AMS) vs. angioplasty (AMS-INSIGHT 1
trial)145 indicated that the AMS technology can be safely
applied, but it did not demonstrate efﬁcacy regarding long-
term patency over standard PTA in the infrapopliteal vessels.
Data from 117 patients (147 CLI limbs) showed signiﬁcantly
higher binary restenosis rate at 6 months (68% vs. 42%,
p = 0.01) with a rate of lumen loss that was nearly doubled
(1.4 vs. 0.7mm, p = 0.001). It should be noted that the
AMS stent was not drug-eluting.
Recommendation
The current-generation absorbable metal stent does not
show superiority in long-term patency over standard PTA in
infrapopliteal vessels. Reliable stent design modiﬁcations
are required, and further clinical trials should be
performed before potential widespread application of the
technology. (Level 1b; Grade B)
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4.2.4. Drug-eluting balloon
The concept of using a balloon catheter to directly deliver
an antirestenotic drug at the site of arterial disease is of
paramount interest. The plan to reduce the risk of restenosis
without irreversibly modifying the structure of the vessel is
a new interesting perspective, but limited clinical data are
available.
Two different paclitaxel-coated balloon catheter systems
are currently being compared to standard uncoated PTA
balloon catheter for treatment of infrapopliteal lesion in a
randomised fashion (INPACT-DEEP trial, PICCOLO trial, EURO
CANAL trial).
Various angiographic and clinical efﬁcacy measures will be
evaluated to study whether paclitaxel-coated PTA balloons
effectively inhibit restenosis of BTK arteries. Additionally,
safety and tolerance of the drug-eluting device will be
evaluated. No preliminary data are available.
It is likely that in the near future, the extent of the use
of drug-coated balloons for BTK vessels in daily practice
will be driven by the proof of their efﬁcacy in reducing
the restenosis rate and by the limitations of other available
techniques. However, the clinical effectiveness of the drug-
eluting balloons should be of crucial importance in deciding
whether or not to opt for the device.
Recommendation
Drug-eluting balloon angioplasty is a promising technology
for patients with CLI and infrapopliteal vessel lesions.
However, prior to widespread clinical implementation, the
results of pilot studies should be conﬁrmed by RCTs with
short- and long-term follow-up. (Level 4; Grade D)
5. Non-reconstructive option in CLI
5.1. Lumbar sympathectomy
Lumbar sympathectomy can be performed both chemically
and surgically. Studies directly comparing lumbar sympa-
thectomy to a conservative treatment in CLI patients are
limited. The small number of randomised trials that have
been conducted failed to show beneﬁcial effects on hard
endpoints like amputation rate, mortality or ankle-brachial
pressure index.146,147 However, lumbar sympathectomy has
a beneﬁcial effect on subjective endpoints, such as relief
of rest pain. The latter has consistently been conﬁrmed in
multiple cohort studies. These studies also suggest enhanced
ulcer healing. Chemical and surgical lumbar sympathectomy
seem to perform equally well148 and can also be beneﬁcial
in diabetic patients.149
Recommendation
Lumbar sympathectomy, either surgical or chemical,
should not be considered an option to prevent amputation.
However, chemical lumbar sympathectomy can be consid-
ered in CLI patients not amenable to revascularisation in
order to relieve symptoms. (Level 2a; Grade B)
5.2. Spinal cord stimulation (SCS)
Spinal cord stimulation involves a technique where an
implanted pacemaker activates the dorsal columns of the
spinal cord with an epidural lead. Early studies have
reported a potential role for the device in limb salvage
in patients with CLI. However, a recent meta-analysis of
randomised trials that have studied the effects of SCS
failed to show a beneﬁcial effect on amputation rate or
mortality.150 It has been suggested that some subgroups
could potentially beneﬁt from SCS, but this could not be
conﬁrmed in the meta-analysis. Most randomised studies
showed pain relief in the group treated with SCS compared
to standard care.151 However, complication rates are
considerable (12%) and treatment costs are high.150,152
Recommendation
Evidence is insufﬁcient to recommend spinal cord
stimulation in the treatment of CLI. (Level 1a; Grade A)
5.3. Gene and cell therapy
Regenerative medicine has raised much interest as a
potential therapeutic strategy in patients with peripheral
arterial disease, especially critical limb ischaemia. Both
angiogenic gene and cell therapy have been studied in clini-
cal context after promising results in animal experiments.
Early piloting trials have been carried out for different
gene-based therapies involving vascular endothelial growth
factor (VEGF), ﬁbroblast growth factor (FGF) and hepatocyte
growth factor (HGF), and showed promising results. The
subsequently performed larger trials have generally failed to
conﬁrm the promising ﬁndings of the pilot trials, therefore
gene therapy is still conﬁned to research settings.153 For
example, the large TAMARIS trial randomised 525 patients
with CLI unsuitable for revascularisation to treatment with
non-viral FGF1 or placebo (8 intramuscular injections in the
ischaemic leg, four times with 2-week intervals).154 The trial
could not prove that FGF is effective in reducing major
amputation or death and amputation in these patients.
Studies that investigate the potential use of cell-based
therapies in CLI are very heterogeneous, with varying
amounts of cells administered, different administration
routes, different cell sources and cell types used. Recently,
Fadini et al.155 performed a meta-analysis of clinical
studies using cell-based therapies in patients with peripheral
arterial disease. These studies almost invariably show
improvement of both objective and subjective endpoints;
however, conclusions based on these studies are largely
limited by the small size and mainly non-randomised design
of these studies. Large randomised placebo-controlled trials
focusing on clinically relevant endpoints are needed to
conﬁrm the promising results and to clarify the remaining
questions surrounding cell therapy, such as preferred
administration route and cell source.
Recommendation
There are data to suggest promising potential of cell-
based therapies in patients with CLI. However, prior to
widespread clinical implementation, the results of pilot
studies should be conﬁrmed by large-scale randomised
placebo-controlled trials. Until then, both cell and gene
therapy should be conﬁned to the research setting.
(Level 5; Grade D)
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